<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /data/rsg/nlp/juanmoo1/bin/grobid-0.6.1/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Emilie</forename><surname>Charton</surname></persName>
							<email>echarton@chu-besancon.fr</email>
							<affiliation key="aff0">
								<orgName type="laboratory" key="lab1">Methodology and Quality of Life Unit in Oncology</orgName>
								<orgName type="laboratory" key="lab2">UMR 1098</orgName>
								<orgName type="institution" key="instit1">INSERM</orgName>
								<orgName type="institution" key="instit2">University Hospital of Besançon</orgName>
								<address>
									<settlement>Besançon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="laboratory">UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique</orgName>
								<orgName type="institution" key="instit1">University Bourgogne Franche-Comté</orgName>
								<orgName type="institution" key="instit2">INSERM, EFS BFC</orgName>
								<address>
									<settlement>Besançon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean-Baptiste</forename><surname>Bachet</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Hepato-Gastroenterology</orgName>
								<orgName type="department" key="dep2">Groupe hospitalier Pitié Salpêtrière</orgName>
								<orgName type="institution" key="instit1">Sorbonne University</orgName>
								<orgName type="institution" key="instit2">UPMC University</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pascal</forename><surname>Hammel</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Digestive Oncology</orgName>
								<orgName type="institution">Hôpital Beaujon</orgName>
								<address>
									<settlement>Clichy</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jérôme</forename><surname>Desramé</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Hepato-Gastroenterology</orgName>
								<orgName type="institution">Hôpital Privé Jean Mermoz</orgName>
								<address>
									<settlement>Lyon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Benoist</forename><surname>Chibaudel</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Institut Franco-Britannique</orgName>
								<address>
									<settlement>Levallois-Perret</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Romain</forename><surname>Cohen</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution" key="instit1">AP-HP</orgName>
								<orgName type="institution" key="instit2">Hôpital Saint-Antoine</orgName>
								<orgName type="institution" key="instit3">Sorbonne University</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philippe</forename><surname>Debourdeau</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Institut Saint Catherine</orgName>
								<address>
									<settlement>Avignon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jérome</forename><surname>Dauba</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Hôpital Layne Mont de Marsan</orgName>
								<address>
									<settlement>Mont de Marsan</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thierry</forename><surname>Lecomte</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Hepato-Gastroenterology</orgName>
								<orgName type="institution">Hôpital Trousseau</orgName>
								<address>
									<settlement>Tours</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean-François</forename><surname>Seitz</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">CHU La Timone</orgName>
								<address>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christophe</forename><surname>Tournigand</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">CHU Henri Mondor</orgName>
								<address>
									<settlement>Créteil</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thomas</forename><surname>Aparicio</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Hepato-Gastroenterology</orgName>
								<orgName type="institution">CHU Saint Louis</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Véronique</forename><surname>Guerin-Meyer</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Institut de cancérologie de L&apos;Ouest Paul Papin</orgName>
								<address>
									<settlement>Angers</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julien</forename><surname>Taieb</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Gastroenterology and Digestive Oncology</orgName>
								<orgName type="institution">Hôpital Européen Georges Pompidou</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">|</forename><surname>Julien Volet</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Hepato-Gastroenterology</orgName>
								<orgName type="institution">CHU Robert Debré</orgName>
								<address>
									<settlement>Reims</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christophe</forename><surname>Louvet</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution">Institut Mutualiste Montsouris</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">|</forename><forename type="middle">Amélie</forename><surname>Anota</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory" key="lab1">Methodology and Quality of Life Unit in Oncology</orgName>
								<orgName type="laboratory" key="lab2">UMR 1098</orgName>
								<orgName type="institution" key="instit1">INSERM</orgName>
								<orgName type="institution" key="instit2">University Hospital of Besançon</orgName>
								<address>
									<settlement>Besançon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="laboratory">UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique</orgName>
								<orgName type="institution" key="instit1">University Bourgogne Franche-Comté</orgName>
								<orgName type="institution" key="instit2">INSERM, EFS BFC</orgName>
								<address>
									<settlement>Besançon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="institution">French National Platform of Quality of Life and Cancer</orgName>
								<address>
									<settlement>Besançon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">|</forename><forename type="middle">Franck</forename><surname>Bonnetain</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory" key="lab1">Methodology and Quality of Life Unit in Oncology</orgName>
								<orgName type="laboratory" key="lab2">UMR 1098</orgName>
								<orgName type="institution" key="instit1">INSERM</orgName>
								<orgName type="institution" key="instit2">University Hospital of Besançon</orgName>
								<address>
									<settlement>Besançon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="laboratory">UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique</orgName>
								<orgName type="institution" key="instit1">University Bourgogne Franche-Comté</orgName>
								<orgName type="institution" key="instit2">INSERM, EFS BFC</orgName>
								<address>
									<settlement>Besançon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff17">
								<orgName type="institution">French National Platform of Quality of Life and Cancer</orgName>
								<address>
									<settlement>Besançon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff18">
								<orgName type="laboratory">Methodology and Quality of Life Unit in Oncology (INSERM UMR 1098)</orgName>
								<orgName type="institution">University Hospital of Besançon</orgName>
								<address>
									<addrLine>3 Boulevard Fleming</addrLine>
									<postCode>25030</postCode>
									<settlement>Besançon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="DOI">10.1002/cam4.2311</idno>
					<note type="submission">Received: 30 October 2018 | Revised: 10 May 2019 | Accepted: 15 May 2019</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.1" ident="GROBID" when="2020-10-09T18:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
				<p>This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">| INTRODUCTION</head><p>Pancreatic cancer is a devastating disease with an overall 5year survival of less than 5%. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref> The mortality trend is increasing in both genders, <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b3">4</ref> and pancreatic cancer is one of the most common causes of death from cancer. <ref type="bibr" target="#b4">5</ref> Over the past two decades, gemcitabine monotherapy has been a standard treatment for metastatic pancreatic cancer. <ref type="bibr" target="#b5">6</ref> In 2011, the FOLFIRINOX regimen (fluorouracil, leucovorin, irinotecan, and oxaliplatin) <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b7">8</ref> and the combination of gemcitabine with nab-paclitaxel <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b9">10</ref> demonstrated an improvement in progression-free survival and overall survival compared with gemcitabine alone. These regimens are thus now considered as the standard first-line treatment options in patients with metastatic pancreatic cancer and good general status without marked cholestasis.</p><p>In the randomized, phase II, AFUGEM GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial, nab-paclitaxel plus simplified leucovorin and fluorouracil treatment (sLV5FU2 group) improved the primary endpoint of progression-free survival at 4 months in the first 72 assessable patients in the sLV5FU2 group, and the secondary endpoint of overall survival compared to nab-paclitaxel plus gemcitabine treatment (gemcitabine group). <ref type="bibr" target="#b10">11</ref> At 4 months, 40 (56% [90% confidence interval (CI) 45-66]) out of 72 patients in the sLV5FU2 group were alive and free of disease progression vs 21 (54% [90% CI 40-68]) out of 39 patients in the gemcitabine group. In exploratory analyses, the median progression-free survival was 5.9 months [95% CI 3.6-7.4] in the sLV5FU2 group vs 4.9 months [95% CI 2.1-7.7] in the gemcitabine group. Similarly, the median overall survival was 11.4 months [95%  in the sLV5FU2 group vs 9.2 months [95% CI 6.0-13.6] in the gemcitabine group (exploratory hazard ratio (HR) of 0.61 [95% CI 0.40-0.95]). Although these results appear to be promising for the nab-paclitaxel plus sLV5FU2 combination, it is crucial to study the impact of the treatment on patients' health-related quality of life (HRQoL) over time. In fact, new combinations of drugs can cause adverse events that may deteriorate the patients' perception of their health. Thus, it is particularly important to take the patient's HRQoL level into account in disease management, in order to ensure that the new treatment does not yield a clinical benefit at the cost of reduced quality of life.</p><p>In this context, based on the phase II AFUGEM clinical trial, we report the impact on HRQoL of a first-line therapy combining nab-paclitaxel plus either gemcitabine or sLV5FU2 in patients with previously untreated metastatic pancreatic cancer.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">| METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">| Patients and eligibility criteria</head><p>The AFUGEM study was an open-label, noncomparative, randomized, multicentre, phase II clinical trial,</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding information:</head><p>This work was supported by GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie), Celgene (through grants to GERCOR) and by a grant from the "Institut National du Cancer (INCA 11862)". The GERCOR collaborative group was involved in study design, data collection, data analysis, data interpretation, and writing of the report, and in the decision to submit for publication. Celgene provided funding to GERCOR, but had no role in any part of study design, data collection, data analysis, data interpretation, or writing of the report.</p><p>previously untreated metastatic pancreatic cancer. Results of progression-free survival at 4 months (primary endpoint) were in favor of the sLV5FU2 group. This paper presents health-related quality of life (HRQoL) data as a secondary endpoint. Methods: HRQoL was assessed using the EORTC QLQ-C30 questionnaire at baseline and at each chemotherapy cycle until the end of treatment. The HRQoL deterioration-free survival (QFS) was used as a modality of longitudinal analysis. QFS was defined as the time between randomization and the first definitive HRQoL score deterioration as compared to the baseline score, or death. Sensitivity analysis was performed excluding death as an event. Univariate Cox models were used to estimate hazard ratios (HRs) and 90% confidence intervals (CIs) of the treatment effect. conducted in 15 centers in France (ClinicalTrials.gov number NCT01964534).</p><p>Eligible patients were required to be aged at least 18 years, with histologically or cytologically proven adenocarcinoma of the pancreas, stage IV disease, no prior therapy for metastatic disease, an Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and presenting adequate hematologic, renal, and liver function. The detailed eligibility criteria have previously been reported. <ref type="bibr" target="#b11">12</ref> The protocol was approved by the French Ethics Committee and written informed consent was obtained from all patients before randomization.</p><p>Using a minimization technique stratified by center and ECOG performance status, patients were randomly assigned (1:2 ratio) to receive nab-paclitaxel plus gemcitabine (control arm) or nab-paclitaxel plus sLV5FU2 (experimental arm). Both regimens were administered every 28 days and details of the regimens have previously been published. <ref type="bibr" target="#b11">12</ref> The primary endpoint was progression-free survival at 4 months in the first 72 patients in the sLV5FU2 group. Secondary endpoints were objective response, progressionfree survival, overall survival, tolerance and HRQoL.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">| Health-related quality of life assessment</head><p>HRQoL was assessed in each treatment arm using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) cancer-specific questionnaire, <ref type="bibr" target="#b12">13</ref> at baseline and at each chemotherapy cycle until the end of treatment. The QLQ-C30 includes 30 items and assesses global health status, 5 functional scales (physical, role, emotional, cognitive and social functioning) and 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Scores vary from 0 (worst) to 100 (best) for global health status and functional scales, and from 0 (best) to 100 (worst) for the symptom scales.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">| Statistical analysis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.1">| Population and statistical considerations</head><p>The intention-to-treat (ITT) population was considered in the HRQoL analysis, that is, all randomized patients regardless of their eligibility criteria and treatment received. Due to the occurrence of missing data, a modified ITT (mITT) population was also defined as all ITT patients with at least one HRQoL score available at baseline. <ref type="bibr" target="#b13">14</ref> Five targeted dimensions were defined a priori in the protocol: physical functioning, emotional functioning, fatigue, pain, and appetite loss. Other dimensions were regarded as being exploratory. <ref type="bibr" target="#b11">12</ref> Although HRQoL was a secondary endpoint in this study, a decision-rule was integrated into the protocol to facilitate interpretation of the results, as follows: HRQoL would be considered as being improved in one arm if at least one time to HRQoL score deterioration among the 5 targeted dimensions was significantly longer without a significantly shorter time to HRQoL score deterioration for the other 4 targeted dimensions.</p><p>Since AFUGEM study is a noncomparative study, P-values of the treatment effect are not reported, while effect sizes are presented for exploratory purposes using HRs and 90% CIs. A 5 point difference in HRQoL scores was considered as the minimal clinically important difference. 15</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.2">| Descriptive analysis at baseline</head><p>Quantitative variables are described using median and range. Qualitative variables are summarized using number and percentage.</p><p>The profile of missing HRQoL data at baseline was explored. <ref type="bibr" target="#b15">16</ref> Analyses were carried out by comparing 2 groups of patients: patients who completed the baseline HRQoL questionnaire (mITT population) versus those who did not. In order to determine whether baseline missing data were dependent on the patients' characteristics, the comparison was performed according to baseline clinical and socio-demographic variables, using the t test or Mann-Whitney nonparametric test for continuous variables, and χ 2 or Fisher's exact test for qualitative variables. P-values &lt; 0.1 were considered as significant. To determine whether baseline missing data depended on patients' health status, the comparison was performed according to overall survival. Overall survival curves were estimated using the Kaplan-Meier estimation method, described using median and 90% CI and compared using the log-rank test. Univariate Cox analysis was used to estimate the HR and 90% CI.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.3">| Longitudinal analysis</head><p>HRQoL deterioration-free survival (QFS) was used as a modality of longitudinal analysis. QFS was defined as the time between randomization and the first HRQoL score deterioration of at least 5 points, as compared to the baseline score, with no further improvement of at least 5 points as compared to the baseline score, or death, whichever occurred first. <ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b17">18</ref> QFS curves were estimated using the Kaplan-Meier estimation method. Univariate Cox models were used to calculate HRs and 90% CIs of the treatment effect. All variables collected at baseline were tested by univariate Cox analysis. The impact of time to toxicity grade 3-4 was also tested by univariate analysis as a timedependent variable.</p><p>Variables significant at a threshold of 10% by univariate analyses were eligible for the multivariate model. The treatment arm was forced in the model. Restricted mean method was used as a supplement to the HR in case of nonrespect of the proportional hazards assumption in the Cox model, and also to ensure the robustness of the model. The difference of restricted mean survival time was estimated with 90% CI. A difference of restricted mean survival time greater than zero favored the sLV5FU2 group. 19</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.4">| Sensitivity analyses</head><p>Several sensitivity analyses were performed.</p><p>First, analyses were repeated excluding death as an event in the QFS definition, which then becomes simply the time until definitive HRQoL deterioration (TUDD). <ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b17">18</ref> Then, QFS analyses were repeated after imputation of baseline missing data in order to consider all ITT patients. Multiple imputations of baseline missing items were performed using the Markov Chain Monte Carlo method taking into account the profile of missing data. Multivariate models were then constructed introducing the same variables as for the longitudinal analysis before treatment of missing data.</p><p>Analyses were performed using SAS (version 9.3) (SAS Institute Inc, Cary, NC) and R (version 3.3.1) software.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">| RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">| Study population</head><p>Between December 2013 and October 2014, 114 patients were randomized: 39 in the gemcitabine group and 75 in the sLV5FU2 group. Sixty-four patients (56.1%) completed the QLQ-C30 questionnaire at baseline, 22 patients (56.4%) in the gemcitabine group, and 42 (56.0%) in the sLV5FU2 group <ref type="figure">(Figure 1)</ref>. Patients in the sLV5FU2 group completed the questionnaire longer after compared to the gemcitabine group. Indeed, there were more patients included in this treatment arm due to the ratio 1:2 and the median overall survival was significantly longer in this treatment arm. The median age was 66 years (range 45-86) and 70 patients (61.4%) were men. The baseline characteristics of the patients are described according to baseline HRQoL availability in <ref type="table">Table 1</ref>. Baseline HRQoL level was similar between treatment arms <ref type="table">(Table S1</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">| Missing data analysis</head><p>Regarding the baseline characteristics, patients with available baseline HRQoL differed from other patients in terms of aspartate aminotransferase (P = 0.037), gamma-glutamyl transpeptidase (P = 0.086) and cancer antigen 19-9 (P = 0.039) ( <ref type="table">Table 1</ref>  <ref type="figure">(Figure 2</ref>). Thus, we could suppose that missing data at baseline depend only on patients' baseline characteristics.  <ref type="figure">(Figure 3)</ref>. Similar trends were observed for all the other dimensions, except for constipation, which had a HR of 1.04 [90% CI 0.64-1.69] <ref type="table">(Table S2</ref>). Multivariate analyses showed significantly shorter QFS among patients with the following <ref type="table">(Table S3)</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">| Longitudinal analysis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>F I G U R E 1 CONSORT diagram for EORTC QLQ-C30</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4">| Sensitivity analysis</head><p>In the sensitivity analysis excluding death as an event, TUDD results were significantly in favor of the sLV5FU2 group for physical functioning (HR = 0.51 [90% CI 0.27-0.97]) and pain (HR = 0.26 [90% CI 0.09-0.74]) <ref type="table">(Table S4)</ref>. A trend toward longer TUDD in favor of the sLV5FU2 group among all other dimensions was observed, except for constipation. After imputation of baseline missing data, results of the QFS analysis by treatment arm were similar to those obtained in the mITT population <ref type="table">(Table S2)</ref>.</p><p>Multivariate analyses after multiple imputations were in accordance with those obtained in the mITT population <ref type="table">(Table S3)</ref>. Results showed significantly shorter QFS among patients with the following: , without a significantly shorter TUDD for the other three targeted dimensions.</p><p>In the NAPOLI-1 phase III clinical trial in metastatic pancreatic cancer also comparing different combinations of chemotherapy, reported that liposomal irinotecan plus 5fluorouracil and leucovorin maintained HRQoL as assessed with the QLQ-C30 versus 5-fluorouracil and leucovorin while improved overall survival. <ref type="bibr" target="#b19">20</ref> However, this trial was performed in second-line treatment and thus is not completely similar to the AFUGEM study. In another phase III trial comparing gemcitabine to the PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen suggested that the combination improved overall survival while providing more grade 3-4 neutropenia and thrombocytopenia. <ref type="bibr" target="#b20">21</ref> The impact of the treatment on HRQoL was thus important to study and the authors reported a maintained HRQoL using also the QLQ-C30 among other questionnaires. <ref type="bibr" target="#b21">22</ref> Thus, our results are consistent with other studies using similar chemotherapy combinations.</p><p>Moreover, these results are consistent with the tolerable toxicity profile of the combination nab-paclitaxel plus sLV5FU2 highlighted previously. <ref type="bibr" target="#b10">11</ref> These physician-reported toxicities are thus in accordance with the patients' perception of their own HRQoL. However, only general symptoms related to cancer were assessed using the QLQ-C30 questionnaire and specific pancreatic cancer symptoms, such as altered bowel habits or indigestion symptoms, could not be captured. Although the EORTC pancreatic cancer module was available at the time of the study, <ref type="bibr" target="#b22">23</ref> it was not administered in this phase II trial to limit the patient burden and thus, occurrence of missing data.</p><p>The main limitation of this study was the relatively low proportion (56.1%) of questionnaires completed at baseline. However, the completion rate was similar in both treatment arms. A likely explanation could be that the first two HRQoL assessment times were at very short interval (ie, at randomization and day one of the first chemotherapy cycle) and this may have caused some confusion between these two time points at the time of data collection. The completion rate over time was close to those observed in other clinical trials in pancreatic cancer, such as in a phase II clinical trial in resectable or borderline resectable pancreatic cancer patients using also the QLQ-C30 questionnaire to assess HRQoL among other questionnaires. <ref type="bibr" target="#b23">24</ref> These missing data also had a direct impact on the population for analysis. It was required to define a modified ITT population including all ITT patients with a baseline HRQoL score available. However, it is recommended that the ITT population be studied in order to best reflect the treatment effect without inducing bias. 14 It is therefore essential to verify that the modified ITT is representative of the ITT population.</p><p>We addressed this issue in the sensitivity analysis, using multiple imputations. The profile of missing data was explored and was dealt only at baseline, and we hypothesized that missing data depended on the baseline characteristics of the patients themselves. Our results showed a trend toward longer QFS in favor of the sLV5FU2 group for 14 out of 15 dimensions, in analyses before and after treatment of missing data. Thus, the occurrence of missing data does not appear to have biased the results. In fact, determining the mechanism of missing data is of fundamental importance to identify the appropriate strategy for analysis of these missing data, <ref type="bibr" target="#b24">25,</ref><ref type="bibr" target="#b25">26</ref> but this remains rare in the analysis of HRQoL in oncology clinical trials. <ref type="bibr" target="#b26">27</ref> Inadequate consideration and handling of missing data in the analysis can bias the results. <ref type="bibr" target="#b24">25,</ref><ref type="bibr" target="#b27">28</ref> In the future, although it is a wellknown fact, it remains important to find the necessary means in the HRQoL data collection during the study to avoid missing data. HRQoL is now recognized as a key endpoint and decision criterion, and should be assessed as rigorously as other, classical biological and clinical endpoints that are required in clinical trials.</p><p>Another important point was the consideration of death in the time to HRQoL deterioration method. In this study, two approaches were adopted: first, excluding death, and second, considering death as an event within definition of time to HRQoL deterioration. Since a large number of deaths were observed, considering death as an event seemed to be the most appropriate solution and thus was retained as our main analysis. However, future research must pay greater attention to the consideration of death, for example by exploring the competing risk between death and deterioration of HRQoL.</p><p>In conclusion, this study suggests that nab-paclitaxel plus simplified leucovorin and fluorouracil does not have a negative impact on HRQoL compared to nab-paclitaxel plus gemcitabine. Thus, this combination of chemotherapy does not yield a clinical benefit at the cost of reduced quality of life.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>Results: Between 2013 and 2014, 114 patients were randomized in a 1:2 ratio (39 in the gemcitabine group and 75 in the sLV5FU2 group). Patients in the sLV5FU2 group seemed to present longer QFS than those of the gemcitabine group for 14 out of 15 dimensions, with HRs &lt; 1. Results of the sensitivity analysis excluding death as an event were significantly in favor of the sLV5FU2 group for physical functioning (HR = 0.51 [90% CI 0.27-0.97]) and pain (HR = 0.26 [90% CI 0.09-0.74]). Conclusion: The nab-paclitaxel plus simplified leucovorin and fluorouracil combination had no negative impact in exploratory HRQoL analyses. K E Y W O R D S clinical trial, deterioration-free survival, metastatic, pancreatic cancer, quality of life | 5081 CHARTON eT Al.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head></head><label></label><figDesc>Baseline characteristics of patients according to the availability of their baseline health-related quality of life (HRQoL) questionnaire</figDesc><table><row><cell>CHARTON eT Al.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>| 5083</cell></row><row><cell cols="3">T A B L E 1 Baseline HRQoL available</cell><cell>HRQoL not available</cell><cell></cell><cell></cell></row><row><cell></cell><cell>(n = 64)</cell><cell></cell><cell>(n = 50)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>n</cell><cell>%</cell><cell>n</cell><cell>%</cell><cell>P</cell></row><row><cell>Gender</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell>38</cell><cell>59.4</cell><cell>32</cell><cell>64.0</cell><cell>0.615</cell></row><row><cell>Women</cell><cell>26</cell><cell>40.6</cell><cell>18</cell><cell>36.0</cell><cell></cell></row><row><cell>Arm</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Gemcitabine</cell><cell>22</cell><cell>34.4</cell><cell>17</cell><cell>34.0</cell><cell>0.967</cell></row><row><cell>sLV5FU2</cell><cell>42</cell><cell>65.6</cell><cell>33</cell><cell>66.0</cell><cell></cell></row><row><cell>ECOG Perormance Status</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0</cell><cell>24</cell><cell>37.5</cell><cell>13</cell><cell>26.0</cell><cell>0.193</cell></row><row><cell>1, 2</cell><cell>40</cell><cell>62.5</cell><cell>37</cell><cell>74.0</cell><cell></cell></row><row><cell>Pain</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>36</cell><cell>56.3</cell><cell>21</cell><cell>42.0</cell><cell>0.131</cell></row><row><cell>No</cell><cell>28</cell><cell>43.7</cell><cell>29</cell><cell>58.0</cell><cell></cell></row><row><cell>Jaundice</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>2</cell><cell>3.1</cell><cell>4</cell><cell>8.0</cell><cell>0.402 c</cell></row><row><cell>No</cell><cell>62</cell><cell>96.9</cell><cell>46</cell><cell>92.0</cell><cell></cell></row><row><cell>Ascites</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>4</cell><cell>6.3</cell><cell>2</cell><cell>4.0</cell><cell>0.694 c</cell></row><row><cell>No</cell><cell>60</cell><cell>93.7</cell><cell>48</cell><cell>96.0</cell><cell></cell></row><row><cell>Hemoglobin</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Normal</cell><cell>39</cell><cell>60.9</cell><cell>30</cell><cell>60.0</cell><cell>0.919</cell></row><row><cell>Abnormal a</cell><cell>25</cell><cell>39.1</cell><cell>20</cell><cell>40.0</cell><cell></cell></row><row><cell>Platelets</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Normal</cell><cell>52</cell><cell>81.3</cell><cell>questionnaire 44</cell><cell>88.0</cell><cell>0.327</cell></row><row><cell>Abnormal a</cell><cell>12</cell><cell>18.7</cell><cell>6</cell><cell>12.0</cell><cell></cell></row><row><cell>Total bilirubin</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Normal</cell><cell>52</cell><cell>81.3</cell><cell>41</cell><cell>82.0</cell><cell>0.918</cell></row><row><cell>Abnormal b</cell><cell>12</cell><cell>18.7</cell><cell>9</cell><cell>18.0</cell><cell></cell></row><row><cell>Alkaline phosphatase</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Normal</cell><cell>31</cell><cell>49.2</cell><cell>20</cell><cell>40.8</cell><cell>0.376</cell></row><row><cell>Abnormal b</cell><cell>32</cell><cell>50.8</cell><cell>29</cell><cell>59.2</cell><cell></cell></row><row><cell>Aspartate aminotransferase</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Normal</cell><cell>51</cell><cell>79.7</cell><cell>31</cell><cell>62.0</cell><cell>0.037</cell></row><row><cell>Abnormal b</cell><cell>13</cell><cell>20.3</cell><cell>19</cell><cell>38.0</cell><cell></cell></row><row><cell>Alanine aminotransferase</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Normal</cell><cell>45</cell><cell>70.3</cell><cell>33</cell><cell>66.0</cell><cell>0.623</cell></row><row><cell>Abnormal b</cell><cell>19</cell><cell>29.7</cell><cell>17</cell><cell>34.0</cell><cell></cell></row><row><cell>Albumin</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Normal</cell><cell>39</cell><cell>60.9</cell><cell>36</cell><cell>73.5</cell><cell>0.162</cell></row><row><cell>Abnormal a</cell><cell>25</cell><cell>39.1</cell><cell>13</cell><cell>26.5</cell><cell></cell></row><row><cell>Carcinoembryonic antigen</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(Continues)</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head></head><label></label><figDesc>Kaplan-Meier curves of health-related quality of life deterioration-free survival (QFS). HR, hazard ratio; 90% CI, 90% confidence interval In this QFS analysis performed on the population of the AFUGEM study, there was no negative impact on HRQoL in patients who received the combination of nab-paclitaxel plus sLV5FU2. When excluding death as an event, we found that this combination improved the patients' HRQoL level compared to gemcitabine group in terms of the decision-rule.</figDesc><table><row><cell>T A B L E 1 (Continued)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="2">Baseline HRQoL available</cell><cell>HRQoL not available</cell><cell></cell><cell></cell></row><row><cell></cell><cell>(n = 64)</cell><cell></cell><cell>(n = 50)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>n</cell><cell>%</cell><cell>n</cell><cell>%</cell><cell>P</cell></row><row><cell>Normal</cell><cell>23</cell><cell>38.3</cell><cell>20</cell><cell>46.5</cell><cell>0.407</cell></row><row><cell>Abnormal b</cell><cell>37</cell><cell>61.7</cell><cell>23</cell><cell>53.5</cell><cell></cell></row><row><cell cols="4">Age (years) f Body mass index (kg/m 2 ) f Neutrophils (/mm 3 ) f Creatinine (μmol/L) f Gamma-glutamyl transpepti-dase (U/L) f Cancer antigen 19-9 (UI/L) f A χ 2 test is used unless indicated otherwise. 64 64 64 64 61 61 a abnormally low or high levels b abnormally high level c Fisher's exact test d t test e Mann-Whitney nonparametric test; sLV5FU2, simplified leucovorin and fluorouracil 65.6 (47-85) 23.0 (16-33) 5425.0 (2592-19704) 50 50 50 66.5 (42-135) 50 134.0 (14-1564) 44 475.2 (2-481206) 44 f Median (range) for continuous variables. F I G U R E 2 Overall survival curves according to baseline health-related quality of life (HRQoL) availability. HR, hazard ratio; 90% CI, 90% confidence interval cantly longer for 2 dimensions, namely physical functioning (HR = 0.51 [90% CI 0.27-0.97]) and pain (HR = 0.26 [90% F I G U R E 3 In fact, among the 5 targeted dimensions, TUDD was signifi-CI 0.09-0.74])</cell><cell cols="2">66.4 (45-86) 23.5 (16-32) 5707.0 (1624-12168) 0.690 e 0.702 d 0.610 d 66.2 (29-140) 0.671 e 204.5 (15-920) 0.086 e 1391.0 (5-214000) 0.039 e</cell></row><row><cell cols="3">• abnormally low level of albumin for emotional function-</cell><cell cols="3">• neutrophils level greater than 5590.0/mm 3 for pain</cell></row><row><cell cols="3">ing (HR = 2.38 [90% CI 1.60-3.54]) and appetite loss</cell><cell cols="2">(HR = 1.63 [90% CI 1.14-2.34]).</cell><cell></cell></row><row><cell cols="3">(HR = 2.04 [90% CI 1.38-3.02]), • abnormally low level of hemoglobin for fatigue (HR = 1.47 [90% CI 1.02-2.11]) and pain (HR = 2.19 [90% CI 1.48-3.23]),</cell><cell cols="3">• An abnormally high level of aspartate aminotransfer-Results also showed significantly longer QFS among patients ase for emotional functioning (HR = 1.50 [90% CI with a creatinine level greater than 66.2 μmol/L for fatigue 1.01-2.23]), (HR = 0.60 [90% CI 0.41-0.89]).</cell></row></table><note></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGMENTS</head><p>The authors thank Fiona Ecarnot (EA3920, University Hospital Besancon, University of Franche-Comté, Besançon, France) for editorial assistance.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>| 5087</head><p>CHARTON eT Al.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICT OF INTEREST</head><p>J-BB has received personal fees from Amgen, Bayer, Celgene, Merck Serono, Roche, Sanofi, Servier, and nonfinancial support from Amgen, Merck Serono, and Roche. PH has received grants from Celgene and Roche; personal fees from Baxalta, Celgene, Ipsen, Lilly, Merck Serono, Novartis, and Pfizer; and nonfinancial support from Celgene, Ipsen, Merck Serono, Novartis, and Pfizer. BC has received personal fees from Bayer, Kantar Health, Kephren, Lilly, Sanofi, and nonfinancial support from Amgen, Merck Serono, and Roche. PD has received grants from DRCD Paris and personal fees from ITAC CME. J-FS has received personal fees from Bayer, Celgene, Lilly, Novartis, Pfizer, and Servier, and nonfinancial support from Roche. JT has received personal fees from Amgen, Celgene, Baxalta, Merck Serono, Sanofi, Sirtex, and Roche. CL received personal fees from Celgene, Roche, and Sanofi. FB received grants from Novartis and Roche; personal fees from BMS, Celgene, Integragen, Ipsen, Janssen, Merck Serono, Nestle, Novartis, and Roche; and nonfinancial support from Celgene, Ipsen, Merck Serono, Novartis, and Roche. All other authors declare no conflict of interest.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AUTHOR CONTRIBUTIONS</head><p>Emilie Charton: Formal analysis, writing -original draft, and writing -review and editing. Jean-Baptiste Bachet: Conceptualization, data curation, funding acquisition, resources, supervision, validation, writing -original draft, and writing -review and editing. Pascal Hammel: Conceptualization, resources, and writing -review and editing. Jérôme Desramé: Resources, and writing -review and editing. Benoist Chibaudel: Resources, and writing -review and editing. Romain Cohen: Writing -review and editing. Philippe Debourdeau: Resources, and writing -review and editing. Jérome Dauba: Resources, and writing -review and editing. Thierry Lecomte: Resources, and writing -review and editing. Jean-François Seitz: Resources, and writingreview and editing. Christophe Tournigand: Resources, and writing -review and editing. Thomas Aparicio: Resources, and writing -review and editing. Véronique Guerin-Meyer: Resources, and writing -review and editing. Julien Taieb: Resources, and writing -review and editing. Julien Volet: Resources, and writing -review and editing. Christophe Louvet: Conceptualization, resources, and writing -review and editing. Amélie Anota: Formal analysis, supervision, validation, writing -original draft, and writing -review and editing. Franck Bonnetain: Conceptualization, methodology, resources, supervision, validation, writing -original draft, and writing -review and editing.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DATA AVAILABILITY STATEMENT</head><p>Data are unsuitable for public deposition due to ethical and legal restrictions and are therefore available upon request with the signature of a data privacy form. To request the data, the readers may contact Prof. Jean-Baptiste Bachet (jeanbaptiste.bachet@aphp.fr).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ORCID</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Emilie Charton</head><p>https://orcid.org/0000-0003-0259-8811</p><p>Amélie Anota https://orcid.org/0000-0001-6896-1367</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SUPPORTING INFORMATION</head><p>Additional supporting information may be found online in the Supporting Information section at the end of the article. </p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cancer of the pancreas: a dilemma in treatment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Cooperman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Surg Clin North Am</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="107" to="115" />
			<date type="published" when="1981" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Carpelan-Holmström</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Nordling</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Pukkala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="385" to="387" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">European cancer mortality predictions for the year 2014</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Malvezzi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Bertuccio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Levi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">La</forename><surname>Vecchia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Negri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol Off J Eur Soc Med Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1650" to="1656" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Malvezzi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Bertuccio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Rosso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol Off J Eur Soc Med Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="779" to="786" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Colombet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Soerjomataram</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer Oxf Engl</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="356" to="387" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">A</forename><surname>Burris</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Andersen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol Off J Am Soc Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="2403" to="2413" />
			<date type="published" when="1997" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Conroy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Desseigne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ychou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="1817" to="1825" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Gourgou-Bourgade</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Bascoul-Mollevi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Desseigne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol Off J Am Soc Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="23" to="29" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Von</forename><surname>Hoff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">D</forename><surname>Ervin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Arena</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="issue">18</biblScope>
			<biblScope unit="page" from="1691" to="1703" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: longterm survival from a phase III trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Goldstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>El-Maraghi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Hammel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="413" to="413" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, openlabel, randomised phase 2 trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-B</forename><surname>Bachet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Hammel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Desramé</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="337" to="346" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-B</forename><surname>Bachet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Chibaudel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Bonnetain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">653</biblScope>
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">K</forename><surname>Aaronson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Ahmedzai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Bergman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="365" to="376" />
			<date type="published" when="1993" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Statistical Challenges in the Analysis of Health-Related Quality of Life in Cancer Clinical Trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Bonnetain</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Fiteni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Efficace</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Anota</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="1953" to="1956" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Interpreting the significance of changes in health-related quality-of-life scores</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Osoba</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Rodrigues</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Myles</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Zee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Pater</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol Off J Am Soc Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="139" to="144" />
			<date type="published" when="1998" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m" type="main">Statistical analysis with missing data</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Little</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">B</forename><surname>Rubin</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2002" />
			<publisher>John Wiley &amp; Sons</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Bonnetain</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Dahan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Maillard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="2753" to="2762" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Anota</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Hamidou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Paget-Bailly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="5" to="18" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Trinquart</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Jacot</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">C</forename><surname>Conner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Porcher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol Off J Am Soc Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="1813" to="1819" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Hubner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Cubillo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-F</forename><surname>Blanc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer Oxf Engl</title>
		<imprint>
			<biblScope unit="volume">2019</biblScope>
			<biblScope unit="issue">106</biblScope>
			<biblScope unit="page" from="24" to="33" />
			<date type="published" when="1990" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Reni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Cordio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Milandri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="369" to="376" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Reni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Bonetto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Cordio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pancreatology</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="454" to="463" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Fitzsimmons</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">D</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>George</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer Oxf Engl</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="939" to="941" />
			<date type="published" when="1999" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">E</forename><surname>Serrano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Herman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">A</forename><surname>Griffith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="270" to="277" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Investigating the missing data mechanism in quality of life outcomes: a comparison of approaches</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Fielding</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">M</forename><surname>Fayers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">R</forename><surname>Ramsay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Health Qual Life Outcomes</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">57</biblScope>
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Reporting and dealing with missing quality of life data in RCTs: has the picture changed in the last decade?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Fielding</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ogbuagu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Sivasubramaniam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Maclennan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">R</forename><surname>Ramsay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Qual Life Res Int J Qual Life Asp Treat Care Rehabil</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2977" to="2983" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Methodology of healthrelated quality of life analysis in phase III advanced non-smallcell lung cancer clinical trials: a critical review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Fiteni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Anota</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Westeel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Bonnetain</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">122</biblScope>
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">A review of RCTs in four medical journals to assess the use of imputation to overcome missing data in quality of life outcomes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Fielding</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Maclennan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">R</forename><surname>Ramsay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trials</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">51</biblScope>
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
